Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy

• Published in: Journal of Venomous Animals and Toxins including Tropical Diseases
• Main Authors: Jean-Philippe Chippaux, Leslie V Boyer, Alejandro Alagón
• Format: Article in Journal/Newspaper
• Language: English
• Published: SciELO 2015
• Subjects: Ebola; Epidemics; Immunotherapy; Prophylaxis; Africa; Arctic medicine. Tropical medicine; RC955-962; Toxicology. Poisons; RA1190-1270; Zoology; QL1-991; Arctic
• Online Access: https://doi.org/10.1186/s40409-015-0003-1; https://doaj.org/article/7b461b4fd10e4b67a36d055877184494

Background Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa. Methods We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products. Results Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its potential has been incompletely evaluated, considering the overall experience and recent improvement of immunotherapy. Development and use of heterologous serum derivatives could protect people exposed to Ebola viruses with reasonable cost and logistics. Conclusion Hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as treatment for exposure to the Ebola virus.